Related Experiment Video
Updated: Jun 22, 2025
06:38
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
Published on: August 4, 2022
2.3K
Multifunctional Cerium Oxide Nanozyme for Synergistic Dry Eye Disease Therapy
Haoyu Zou1, Yueze Hong1, Baoqi Xu1
1National Engineering Research Center of Ophthalmology and Optometry, School of Biomedical Engineering, School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
ACS Applied Materials & Interfaces
|July 1, 2024
Summary
This study introduces a novel cerium oxide nanozyme loaded with diquafosol sodium (DQS) for synergistic dry eye disease (DED) treatment. The nanozyme effectively scavenges reactive oxygen species (ROS) and restores tear film stability, outperforming existing DQS solutions.
Area of Science:
- Ophthalmology
- Nanotechnology
- Biomedical Engineering
Background:
- Dry eye disease (DED) is a multifactorial condition linked to tear film instability and oxidative stress.
- Current treatments aim to restore tear film integrity, but synergistic approaches are needed.
Purpose of the Study:
- To develop a novel cerium oxide nanozyme loaded with diquafosol sodium (DQS) for enhanced dry eye disease (DED) treatment.
- To investigate the synergistic antioxidant and tear film-stabilizing effects of the DQS-loaded nanozyme (Ce@PBD).
Main Methods:
- Fabrication of cerium oxide nanozymes using specific agents and immobilization of DQS via a phenylborate ester bond.
- Evaluation of Ce@PBD's ROS scavenging, antioxidant, and anti-inflammatory properties.
- Assessment of Ce@PBD's efficacy in animal models, measuring corneal epithelium restoration, goblet cell count, and tear secretion.
Main Results:
- Ce@PBD demonstrated potent ROS scavenging mimicking superoxide dismutase and catalase, exhibiting strong antioxidant and anti-inflammatory effects.
- DQS released from Ce@PBD stimulated P2Y2 receptors, improving tear film stability.
- Animal studies showed Ce@PBD significantly restored corneal epithelium, increased goblet cells, and promoted tear secretion, surpassing commercial DQS solutions.
Conclusions:
- The developed DQS-loaded cerium oxide nanozyme (Ce@PBD) offers a promising synergistic therapeutic strategy for dry eye disease (DED).
- Ce@PBD effectively addresses both oxidative stress and tear film instability, key factors in DED pathogenesis.
